285 related articles for article (PubMed ID: 24626813)
1. Level of urinary liver-type fatty acid-binding protein is associated with cardiac markers and electrocardiographic abnormalities in type-2 diabetes with chronic kidney disease stage G1 and G2.
Maeda Y; Suzuki A; Ishii J; Sekiguchi-Ueda S; Shibata M; Yoshino Y; Asano S; Hayakawa N; Nakamura K; Akiyama Y; Kitagawa F; Sakuishi T; Fujita T; Hashimoto S; Ozaki Y; Itoh M
Heart Vessels; 2015 May; 30(3):362-8. PubMed ID: 24626813
[TBL] [Abstract][Full Text] [Related]
2. NT-proBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults.
Bansal N; Katz R; Dalrymple L; de Boer I; DeFilippi C; Kestenbaum B; Park M; Sarnak M; Seliger S; Shlipak M
Clin J Am Soc Nephrol; 2015 Feb; 10(2):205-14. PubMed ID: 25605700
[TBL] [Abstract][Full Text] [Related]
3. Predicting acute kidney injury using urinary liver-type fatty-acid binding protein and serum N-terminal pro-B-type natriuretic peptide levels in patients treated at medical cardiac intensive care units.
Naruse H; Ishii J; Takahashi H; Kitagawa F; Nishimura H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Hayashi M; Sarai M; Watanabe E; Izawa H; Ozaki Y
Crit Care; 2018 Aug; 22(1):197. PubMed ID: 30119691
[TBL] [Abstract][Full Text] [Related]
4. Association of urinary liver-type fatty acid-binding protein with renal functions and antihyperglycemic drug use in type 2 diabetic nephropathy patients.
Hirowatari K; Kawano N
Int Urol Nephrol; 2023 Aug; 55(8):2111-2118. PubMed ID: 36840803
[TBL] [Abstract][Full Text] [Related]
5. Nonalbuminuric proteinuria as a biomarker for tubular damage in early development of nephropathy with type 2 diabetic patients.
Kim SS; Song SH; Kim IJ; Kim WJ; Jeon YK; Kim BH; Kwak IS; Lee EK; Kim YK
Diabetes Metab Res Rev; 2014 Nov; 30(8):736-41. PubMed ID: 24687388
[TBL] [Abstract][Full Text] [Related]
6. Urinary markers in the early stage of nephropathy in patients with childhood-onset type 1 diabetes.
Suh JS; Kim SH; Cho KS; Jung IA; Cho WK; Jeon YJ; Jung MH; Suh BK
Pediatr Nephrol; 2016 Apr; 31(4):623-31. PubMed ID: 26525196
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of NGAL, L-FABP and albuminuria in predicting GFR decline in type 2 diabetes mellitus patients.
Chou KM; Lee CC; Chen CH; Sun CY
PLoS One; 2013; 8(1):e54863. PubMed ID: 23349979
[TBL] [Abstract][Full Text] [Related]
8. Serum N-terminal Pro-brain Natriuretic Peptide Level is Associated with the Development of Chronic Kidney Diseases in Patients with Type 2 Diabetes.
Sawada R; Hashimoto Y; Senmaru T; Tanaka M; Ushigome E; Yamazaki M; Fukui M
Endocr Metab Immune Disord Drug Targets; 2018; 18(6):590-595. PubMed ID: 29697035
[TBL] [Abstract][Full Text] [Related]
9. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.
Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H
Diabetes Care; 2005 Nov; 28(11):2728-32. PubMed ID: 16249547
[TBL] [Abstract][Full Text] [Related]
10. Urinary ACE2 is associated with urinary L-FABP and albuminuria in patients with chronic kidney disease.
Abe M; Maruyama N; Oikawa O; Maruyama T; Okada K; Soma M
Scand J Clin Lab Invest; 2015 Sep; 75(5):421-7. PubMed ID: 26067610
[TBL] [Abstract][Full Text] [Related]
11. Relationship of urinary liver-type fatty acid-binding protein with cardiovascular risk factors in the Japanese population without chronic kidney disease: Sasayama study.
Kubota Y; Higashiyama A; Marumo M; Konishi M; Yamashita Y; Okamura T; Miyamoto Y; Wakabayashi I
BMC Nephrol; 2021 May; 22(1):189. PubMed ID: 34020611
[TBL] [Abstract][Full Text] [Related]
12. Urine liver fatty acid binding protein and chronic kidney disease progression.
Khatir DS; Bendtsen MD; Birn H; Nørregaard R; Ivarsen P; Jespersen B; Buus NH
Scand J Clin Lab Invest; 2017 Nov; 77(7):549-554. PubMed ID: 28745927
[TBL] [Abstract][Full Text] [Related]
13. Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes.
von Eynatten M; Baumann M; Heemann U; Zdunek D; Hess G; Nawroth PP; Bierhaus A; Humpert PM
Eur J Clin Invest; 2010 Feb; 40(2):95-102. PubMed ID: 19912308
[TBL] [Abstract][Full Text] [Related]
14. Elevation of urinary liver-type fatty acid-binding protein as predicting factor for occurrence of contrast-induced acute kidney injury and its reduction by hemodiafiltration with blood suction from right atrium.
Katoh H; Nozue T; Kimura Y; Nakata S; Iwaki T; Kawano M; Kawashiri MA; Michishita I; Yamagishi M
Heart Vessels; 2014 Mar; 29(2):191-7. PubMed ID: 23604313
[TBL] [Abstract][Full Text] [Related]
15. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.
Takashima H; Yoshida Y; Nagura C; Furukawa T; Tei R; Maruyama T; Maruyama N; Abe M
Diab Vasc Dis Res; 2018 Sep; 15(5):469-472. PubMed ID: 29923427
[TBL] [Abstract][Full Text] [Related]
16. High-sensitive cardiac troponin, NT-proBNP, hFABP and copeptin levels in relation to glomerular filtration rates and a medical record of cardiovascular disease.
Bjurman C; Petzold M; Venge P; Farbemo J; Fu ML; Hammarsten O
Clin Biochem; 2015 Mar; 48(4-5):302-7. PubMed ID: 25637776
[TBL] [Abstract][Full Text] [Related]
17. Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study.
Fu WJ; Xiong SL; Fang YG; Wen S; Chen ML; Deng RT; Zheng L; Wang SB; Pen LF; Wang Q
Endocrine; 2012 Feb; 41(1):82-8. PubMed ID: 21779943
[TBL] [Abstract][Full Text] [Related]
18. Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure.
Swoboda PP; McDiarmid AK; Erhayiem B; Ripley DP; Dobson LE; Garg P; Musa TA; Witte KK; Kearney MT; Barth JH; Ajjan R; Greenwood JP; Plein S
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28716801
[TBL] [Abstract][Full Text] [Related]
19. Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes.
Jeon YK; Kim MR; Huh JE; Mok JY; Song SH; Kim SS; Kim BH; Lee SH; Kim YK; Kim IJ
J Korean Med Sci; 2011 Feb; 26(2):258-63. PubMed ID: 21286018
[TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
Kobayashi K; Toyoda M; Kimura M; Hatori N; Furuki T; Sakai H; Takihata M; Umezono T; Ito S; Suzuki D; Takeda H; Kanamori A; Degawa H; Yamamoto H; Machimura H; Mokubo A; Chin K; Obana M; Hishiki T; Aoyama K; Nakajima S; Umezawa S; Shimura H; Aoyama T; Sato K; Miyakawa M
Diab Vasc Dis Res; 2019 Jan; 16(1):103-107. PubMed ID: 30284913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
